Engineering therapeutic proteins

Current Opinion in Structural Biology

Volumn 10, Issue 4, 2000, Pages 417-420

  McCafferty, John ^a   Glover, David R ^a  

^a MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN; TRASTUZUMAB;

BIOTECHNOLOGY; CLINICAL TRIAL; DRUG DESIGN; DRUG PROTEIN BINDING; GENETIC ENGINEERING; IMMUNOGENICITY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033928843     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(00)00108-1     Document Type: Review

References (28)

1. Annual report: The World's Biotechnology Companies. Pharma Business, 1999:30-52. This report concisely reviews information on biotechnology companies and their products in the clinic. It tabulates the composition, indication, developer and launch date of the drugs, as well as sales totals for 1998 (contact http://www.pharmabusiness.com for back issues).
2. New Medicines in Development: Biotechnology on World Wide Web URL: http://www.phrma.org/charts/b_c00.html . This is the web site of PhRMA, an organisation representing approximately 100 American Pharmaceutical Companies. "Medicines in Development 2000" is a review that lists products in development by category of product, indication and clinical trial status.
3. Genentech Products on World Wide Web URL http://www.genentech.com/products/ .
4. Shak S., Capon D.J., Hellmiss R., Marsters S.A., Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA. 87:1990;9188-9192.
5. Centocor (Products) on World Wide Web URL http://www.centocor.com .
6. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet. 355:2000;735-740.
7. Novartis "What We Do" on World Wide Web URL http://www.pharma.us.novartis.com/what/ .
8. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525.
9. Protein Design Labs Products in Clinical Development on World Wide Web URL http://www.pdl.com/PDLProducts/ClinTable/clintable.htm .
10. MedImmune Inc. Products on the Market on World Wide Web URL http://www.medimmune.com/medimmune/products/pom.html .
11. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 18:2000;157-162.
12. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 224:1992;487-499.
13. Vaughan T.J., Osbourn J.K., Tempest P.R. Human antibodies by design. Nat Biotechnol. 16:1998;535-539.
14. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 348:1990;552-554.
15. Cambridge Antibody Technology Group Therapeutic Products on World Wide Web URL http://www.cambridgeantibody.com/therapeutics/index.html .
16. Lowman H.B., Wells J.A. Affinity maturation of human growth hormone by monovalent phage display. J Mol Biol. 234:1993;564-578.
17. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFα antibody D2E7. Ann Rheum Dis. 58:1999;170-172. D2E7 is the first antibody derived from phage display to show benefit in the clinic. It is currently in phase III clinical trials for the treatment of rheumatoid arthritis. This article reviews earlier results, in which up to 80% of patients showed clinically significant benefits following intravenous or subcutaneous administration.
18. van de Winkel J.G.J., Bast B., de Gast G.C. Immunotherapeutic potential of bispecific antibodies. Immunol Today. 18:1997;562-564.
19. Medarex Platform Technologies on World Wide Web URL http://www.medarex.com/researchF.html .
20. Ligand Pharmaceuticals (Products) on World Wide Web URL http://www.ligand.com .
21. Murray K.M., Dahl S.L. Recombinant human tumour necrosis factor receptor p75 Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother. 31:1997;1335-1338.
22. Levy Y., Capitant C., Houhou S., Carriere I., Viard J.P., Goujard C., Gastaut J.A., Oksenhendler E., Boumsell L., Gomard E.et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet. 353:1999;1923-1929.
23. Rapilysin-EPAR on World Wide Web URL http://www2.eudra.org/humandocs/humans/EPAR/Rapilysin/Rapilysin.htm .
24. Ciszak E., Beals J.M., Frank B.H., Baker J.C., Carter N.D., Smith G.D. Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. Structure. 3:1995;615-622.
25. Chiron Products on World Wide Web URL http://www.chiron.com/products/index.html .
26. Hall, M. An A to Z of British Medicines Research. London: Association of British Pharmaceutical Industry; 1998. [URL: http://www.abpi.org.uk/publications/patient_info.htm ].
27. Protein Structure Initiative on World Wide Web URL: http://www.structuralgenomics.org/ .
28. Ballinger M.D., Shyamala V., Forrest L.D., Deuter-Reinhard M., Doyle L.V., Wang J.X., Panganiban-Lustan L., Stratton J.R., Apell G., Winter J.A.et al. Semi-rational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol. 17:1999;1199-2104. This article illustrates the feasibility of using selection technology combined with knowledge of receptor signalling to create a peptide agonist of fibroblast growth factor. As well as a requirement for dimerisation, there was a requirement for heparin binding in both natural and mimetic agonists. The marriage of selection/screening technology with biological or structural knowledge is likely to be a feature of future engineered protein therapeutics.